Utilizing Pathway-Directed Therapy in Multiple Myeloma

Key opinion leaders open a discussion surrounding the current treatment landscape of multiple myeloma (MM).

Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study.

Medical experts explore the SWOG-S0777 trial and present an overview of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs bortezomib, lenalidomide, and low-dose dexamethasone (VRd).

Brea C. Lipe, MD, highlights considerations for frail patients when treating for MM.

Raymond Thertulien, MD, PhD, discusses high-risk factors for patients with MM.

Daratumumab can be an effective frontline MM treatment option.

A panel of experts discuss the value of clinical pathways in MM disease management.

Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape.

Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.

Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.

Highlighted are updates in NCCN guidelines for frontline MM treatment strategies.

Dr Lipe shares disparities between academic and community practice settings for patients with MM.

Dr Nadeem provides community and clinical strategies to treat patients with MM.

In the final discussion, expert panelists navigate treatment sequencing in MM treatment strategies.